Lokhov Petr G, Trifonova Oxana P, Balashova Elena E, Maslov Dmitry L, Ugrumov Michael V, Archakov Alexander I
Laboratory of Mass Spectrometric Metabolomic Diagnostics, Institute of Biomedical Chemistry, Moscow, Russia.
Laboratory of Neural and Neuroendocrine Regulations, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow, Russia.
Front Mol Biosci. 2024 Aug 14;11:1407974. doi: 10.3389/fmolb.2024.1407974. eCollection 2024.
In terms of time, cost, and reproducibility of clinical laboratory tests, a mass spectrometric clinical blood metabogram (CBM) enables the investigation of the blood metabolome. Metabogram's components provide clinically relevant information by describing related groups of blood metabolites connected to humoral regulation, the metabolism of lipids, carbohydrates and amines, lipid intake into the organism, and liver function. For further development of the CBM approach, the ability of CBM to detect metabolic changes in the blood in the early stages of Parkinson's disease (PD) was studied in this work. In a case-control study (n = 56), CBM enabled the detection of the signature in blood metabolites related to 1-2.5 clinical stages of PD, according to the modified Hoehn and Yahr scale, which is formed by alterations in eicosanoids, phospholipids and, presumably, in the butadione metabolism. The CBM component-based diagnostic accuracy reached 77%, with a specificity of 71% and sensitivity of 82%. The research results extend the range of disorders for which CBM is applicable and offer new opportunities for revealing PD-specific metabolic alterations and diagnosing early-stage PD.
就临床实验室检测的时间、成本和可重复性而言，质谱临床血液代谢谱（CBM）能够对血液代谢组进行研究。代谢谱的组成部分通过描述与体液调节、脂质、碳水化合物和胺类代谢、机体脂质摄入以及肝功能相关的血液代谢物相关组，提供临床相关信息。为了CBM方法的进一步发展，本研究探讨了CBM在帕金森病（PD）早期检测血液中代谢变化的能力。在一项病例对照研究（n = 56）中，根据改良的Hoehn和Yahr量表，CBM能够检测出与PD临床1 - 2.5期相关的血液代谢物特征，该特征由类花生酸、磷脂以及可能的丁二酮代谢改变形成。基于CBM组分的诊断准确性达到77%，特异性为71%，敏感性为82%。研究结果扩展了CBM适用的疾病范围，并为揭示PD特异性代谢改变和早期PD诊断提供了新机会。
